Capital International Investors
NBIX icon

Capital International Investors’s Neurocrine Biosciences NBIX Stock Holding History

Capital International Investors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-47,027
Closed -$4.41M – 452
2022
Q1 		$4.41M Sell
47,027
-10,550
-18% -$894K ﹤0.01% 434
2021
Q4 		$4.9M Sell
57,577
-389,442
-87% -$35.8M ﹤0.01% 437
2021
Q3 		$42.9M Sell
447,019
-669,144
-60% -$63.2M 0.01% 360
2021
Q2 		$109M Sell
1,116,163
-456,163
-29% -$43.7M 0.02% 293
2021
Q1 		$153M Sell
1,572,326
-1,840,323
-54% -$193M 0.04% 249
2020
Q4 		$327M Sell
3,412,649
-862,827
-20% -$83.3M 0.09% 194
2020
Q3 		$411M Sell
4,275,476
-1,820,920
-30% -$211M 0.13% 153
2020
Q2 		$744M Buy
6,096,396
+76,293
+1% +$8.43M 0.24% 109
2020
Q1 		$521M Buy
6,020,103
+187,960
+3% +$18.4M 0.21% 112
2019
Q4 		$627M Buy
5,832,143
+1,667
+0% +$175K 0.21% 118
2019
Q3 		$525M Buy
5,830,476
+200,122
+4% +$18.7M 0.2% 117
2019
Q2 		$475M Buy
5,630,354
+1,203,754
+27% +$98.8M 0.19% 123
2019
Q1 		$390M Buy
4,426,600
+901,600
+26% +$75.4M 0.17% 137
2018
Q4 		$252M Buy
3,525,000
+3,267,000
+1,266% +$313M 0.13% 157
2018
Q3 		$31.7M Buy
+258,000
New +$29.3M 0.01% 304

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
EVM
Eaton Vance Management Boston, Massachusetts $67.5B AUM 11.44% 1-Year Est. Return

Capital International Investors's NBIX Position: Q2 2022 in Review

Capital International Investors sold out of Neurocrine Biosciences (NBIX) in Q2 2022, closing a stake of 47,027 shares — an estimated $4.41M sold.

Capital International Investors first reported a position in NBIX in Q3 2018 and held it in 15 quarters. The position peaked at $744M in Q2 2020. 438 funds tracked by Wall St. Rank hold NBIX as of Q2 2022.

  • Capital International Investors reported no remaining Neurocrine Biosciences position as of Q2 2022 after selling out during the quarter.
  • Capital International Investors sold 47,027 Neurocrine Biosciences shares in Q2 2022, an estimated $4.41M.
  • Capital International Investors first reported a position in Neurocrine Biosciences in Q3 2018 and held it in 15 quarters.
  • Capital International Investors's Neurocrine Biosciences position peaked at $744M in Q2 2020.
  • 438 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2022.

Based on Capital International Investors's 13F filing for Q2 2022, filed 15 Aug 2022.